Abstract: Sexual function is a major concern in the treatment of penile cancer patients. Although sexual dysfunctions may be present initially, they tend to develop after the treatment of penile lesion, signi®cantly in¯uencing patient's quality of life. From 1981 to 1993 we conducted a prospective study focusing on the normal function of 50 patients (average age of 52 y) with surgically managed penile carcinoma. Preoperative anamnesis showed that 11 patients (22%) had normal impairment previously to the development of the tumour. The treatment of penile lesion consisted of 41 partial penectomy, 8 total penectomy and 1 emasculation; all of them were submitted to bilateral inguinal lymphadenectomy. Among the 39 preoperatively potent patients, 21 (53%) complained of erectile dysfunction when evaluated one year after surgery. All of 18 patients who remained potent had a penile stump larger than 4 cm and none of those with a stump less than 4 cm preserved potency. Preservation of erectile function was negatively associated with tumor stage. Three patients complained of premature ejaculation preoperatively and remained with the same symptom after partial penile amputation.
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Comments: Penile cancer is responsible for almost 20% of male neoplasia in undeveloped countries. 1 Sexual function after partial or total penectomy is always a major concern for patients and doctors. This study shows the importance of a focused anamnesis about sexual function in the preoperative period since 22% of the patients had been impotent even before the development of the tumor. It seems that the minimum size of a sexually functional penile stump is 4 cm and this should be the surgeon's goal without compromising the radicality of the procedure. It is interesting that premature ejaculation remained unchanged after partial penectomy showing that penile nerves section does not correlate with an enlargement of ejaculatory time as had been proposed in the past. Editorial comment: The androgen dependence for the nitric oxide (NO)-mediated process of penile erection in the rat may not refer only to androgens of testicular origin since castration reduces the neurostimulated rat erectile response by only 40±50%. These investigators proposed that androgens or other substances derived from the adrenal gland may contribute to regulating the NO synthase (NOS) pathway involved in the response. In rats treated with adrenalectomy and castration, separately or in combination, with and without hormone replacement, neurostimulated penile erections were most signi®cantly reduced in combined adrenalectomized and castrated animals although this reduction was prevented in similarly treated animals which were replaced with mineralocorticoids and glucocorticoids. Adrenalectomy did not further reduce penile NOS activity measurements from that observed in castrated only animals, although this manipulation in combination with castration was apparently suf®cient to cause a decrease in penile neuronal NOS protein content from baseline levels that were maintained with castration alone. In addition to showing that factors of adrenal origin participate in the erectile mechanism, the investigators have established a role for corticoids and possibly other adrenal substances in this mechanism. The adrenal contribution to effects on the NOS pathway mediating penile erection in the rat may pertain to neuronal NOS expression. However, the absence of an effect on penile NOS activity following adrenal manipulation suggests that the role of adrenal substances in the erectile function of the rat involves mechanisms distinct from NO synthesis and release.
AL Burnett, MD This study evaluated the effect of a new combination of vasoactive agents. 25 mg vasoactive intestinal polypeptide (VIP) with 1 (VIP1) or 2 (VIP2) mg phentolamine mesylate in 70 patients who failed to respond to intracavernosal prostaglandin-E1 (20mg), papaverine (30 mg) and 1 mg phentolamine mesylate. The causes of erectile dysfunction in this group of patients included spinal cord lesion, diabetes, ischaemic heart disease, hypertension or idiopathic causes. Forty seven percent of the patients responded to VIP1 and 20% to VIP2. In total 67% of patients achieved erections suf®cient for sexual intercourse. The most common side-effect was transient facial¯ushing, as it was reported by 53% of the patients. Other side effects were truncal ushing in 9%, bruising in 20% and pain from the injection needle in 11%. It should be noticed that none of the patients experienced priapism.
Editorial Comment: In the era of the new developments in the ®eld of erectile dysfunction, with the oral agent and intraurethral alprostadil already available in the market, little attention has been paid to the group of patients who do not respond to the even most ef®cacious intracavernosal combinations. Available data from an impressive number of clinical trials have shown that the new drugs have limited ef®cacy to the so called`severe cases'. Future oral or intraurethral developments seem extremely dif®cult to cover this group of patients, due to the systemic effects of the drugs. It is also well known that a certain percentage of patients who do not respond to any injectable drug combination, do not favor a penile prosthesis implantation. Such observations make clear the necessity for the development of new, more potent injectables. The
Review of Impotence Literature paper shows that VIP1 & 2 may be useful in such cases, as it is effective, with minor side-effects. The lack of priapism is not surprising, as patients who do not respond to high doses of drug combinations have severe cavernosal veno-occlusive dysfunction. In such patients we are mainly aware of major systemic effects due to systemic absorption of the vasoactive agents. The minor side-effects noticed in the present study make the new combination an attractive alternative to the existing injectable solutions. Crossover studies are necessary to further determine the ef®cacy and safety pro®le of this promising new combination.
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Prevalence and impact of incontinence and impotence following total prostatectomy assessed anonymously by the ICS-Male Questionnaire.
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This study, using the ICS-male questionnaire, assessed the incidence of incontinence and impotence in patients following radical prostatectomy and the impact of these two conditions on patients quality of life. A total of 87 patients (mean age 65 y) were included, who had undergone radical retropubic prostatectomy by the same surgeon, during 8 y period. Eighty-three (95%) of the patients completed the questionnaire. The mean interval between surgery and the completion of the questionnaire was 22 months. Postoperatively, 69% (57 out of the 83) of the patients reported some degree of leakage of urine, but only 34% of them considered incontinence as a problem. Of the 74 patients, who were potent prior to surgery, only 30 remained potent postoperatively (potency rate 41%). However, 10% of all patients considered postoperative impotence to be a serious problem, while 47% stated that it was not a problem at all. Regarding the quality of their postoperative erections, 67% of patients reporting potency had severely reduced rigidity, and only 12% were able to achieve full erections. The authors concluded that the incidence of incontinence and impotence following radical prostatectomy is high, but the impact of these complications appears to be surprisingly low.
Editorial comment: During the last ®fteen years, early diagnosis of prostate cancer has led to an increasing number of patients with post-prostatectomy erectile dysfunction. The introduction of the nerve-sparing technique on the other hand, made this type of surgery more appealing, as it helped not only to preserve potency but also continence. There is certainly a great deal of discussion about the ef®cacy of the technique in preserving potency, as other factors (for example damage of vascular structures) may cause or contribute to postoperative impotence. Other critical issues however, such as patients expectations, have been dismissed. The authors found that most of their patients did not report impotence as a signi®cant complication. In addition, 41% reported potency postoperatively, although only 12% had full erections. Such data demonstrate that many patients considered themselves potent, although their erections were not ®rm enough for vaginal penetration. This observation clearly shows that preoperative potency status and patients desire to preserve potency are critical issues in preoperative counseling. In addition, a more extensive surgery that ultimately will be more effective in removing the tumor should be always considered, while nerve-sparing technique should be performed only in cases where it is equally effective in eradicating the tumor. Today, with several treatment options available for impotence, the ®rst goal in performing radical prostatectomy should be to remove all of the cancer, second to preserve continence (as treatment options are limited) and third to preserve potency D Hatzichristou, MD Review of Impotence Literature
